Answer: A woman was less likely to develop colorectal cancer if she was taking E+P. For every 10,000 women taking estrogen plus progestin, six fewer women will develop colorectal cancer while taking estrogen plus progestin. While reducing the risk developing the risk of developing colorectal cancer is favorable, the colorectal cancer cases which developed in women taking E+P were more advanced; about 76% had spread to lymph nodes or elsewhere in the body, compared to 49% of women on placebo.

The results of a five-year study show that of every 10,000 women per year taking Prempro, there would be: 8 more cases of breast cancer, 7 more cases of heart attacks, 8 more cases of stroke, and 18 more cases of blood clots in the lungs and legs.

Answer: A woman is more likely to develop dementia if she is taking estrogen plus progestin. However, the number of women who actually do develop dementia is relatively modest--45 out of 10,000 women taking estrogen plus progestin each year, compared to 22 out of 10,000 women taking placebo each year. While this difference in rates is important, the overall risk remains small.

Answer: WHIMS includes a study of Estrogen-Alone (without progestin) for women who did not have a uterus before they joined WHI. Final results from the Estrogen-Alone study remain uncertain. Participants in the Estrogen-Alone study are asked to continue to take their study pills and to come in for their regular clinical visits.

The results of a recent fiveyear study showed that of every 10,000 women per year taking Prempro, there would be: 6 fewer cases of colon cancer; and 5 fewer cases of hip fracture. According to the FDA, Prempro, as well as other estrogen and estrogen plus progestin products, remain the most effective products available to treat hot flashes and vaginal symptoms of menopause.

Prempro's manufacturer estimates that approximately 10 million postmenopausal women are taking some form of estrogen, either alone or in combination with a progestin.

In the WHIMS Estrogen-Alone study we found that a woman was more likely to develop dementia if she had been taking active estrogen pills. However, the number of women who actually did develop dementia was small??"37 out of 10,000 women taking estrogen??"alone each year, compared to 25 out of 10,000 women taking placebo each year, or a difference of 12 women. While this difference is important, the number of individual women who were affected was small.

had a hip fracture each year, compared to 15 out of every 10,000 women taking placebo pills each year. Answer: There was no difference in the development of breast cancer during the first 4 years between women taking estrogen plus progestin and those taking placebo pills. After that time, the numbers began to increase. After an average of 5.2 years, there was an increased risk of breast cancer in women taking estrogen plus progestin compared to those taking placebo pills.

Answer: Women who were randomized to receive active hormones were taking conjugated equine estrogens 0.625 mg each day and medroxyprogesterone acetate 2.5 mg each day. This is the most commonly prescribed postmenopausal hormone therapy in the United States for women who have a uterus (used each day by more than six million women).

Answer: Fewer women who took estrogen plus progestin (E+P) developed colorectal cancer than women taking placebo (inactive pills). The cancer cases found in women taking E+P had similar characteristics (looked the same under the microscope) but the tumors had spread more throughout the body than those in the placebo group.

Answer: There is no evidence of an increased risk for breast cancer in women taking active estrogen alone, compared to those taking placebo pills, even after an average of 5.2 years. We do not know whether the long-term effects will differ. The Data Safety and Monitoring Board will continue to review participants' health data every 6 months.

Answer: A woman is more likely to develop breast cancer if she is taking E+P. For every 10,000 women taking estrogen plus progestin, 41 women each year will develop breast cancer as compared to 33 women per year who would develop breast cancer while taking placebo. While this difference in risk is important, the overall risk to an individual woman remains small.

Answer: More women who took estrogen plus progestin (E+P) developed breast cancer than women taking placebo (inactive pills). The cancer cases found in women taking E+P had similar characteristics (looked the same under the microscope), but the tumors were larger and had spread more throughout the body than those in the placebo group.

Answer: In its most recent review of the study data, the WHI Data and Safety Monitoring Board saw an increased risk of breast cancer in women taking estrogen plus progestin. The Board also saw that the previously identified risks for heart attacks, strokes and blood clots to the lungs and legs had persisted. Therefore, in the judgment of the Board, the overall risks outweighed the benefits of taking estrogen plus progestin.

Answer: Women who were randomized to receive active hormones in this study were taking conjugated equine estrogens 0.625 mg each day and medroxyprogesterone acetate 2.5 mg each day (PremPro™). When WHI first began, this was the most commonly prescribed hormonal therapy in the United States for postmenopausal women with a uterus.

The numbers of women who developed heart attacks, strokes, or blood clots in the lungs and legs were higher in women taking estrogen plus progestin. The numbers of women who had hip and other fractures or colorectal cancer were lower in women taking estrogen plus progestin. There were no differences in the number of women who had endometrial cancer (cancer of the lining of the uterus) or in the number of deaths.

irritable bowel syndrome is not a dangerous illness and does not lead to intestinal cancer. There is also no increased risk of becoming sick with intestinal cancer.

Women need estrogen to enhance the quality of their life and remain healthy enough to enjoy it to the maximum.

Again, consult with your physician or medical practitioner before taking any supplements in addition to your prescription.

With the use of any prescription medication, consult your health care provider before starting any program of nutritional supplementation. Many doctors are becoming more familiar with the use of phytoestrogens, such as those contained in Innerharmony, as a gentle supplement to estrogen therapy.

Medifast Plus for Women's Health is a specially designed meal-replacement supplement, specially formulated to relieve and prevent the agonizing symptoms of Menopause. This product provides a safe and effective solution for many symptoms of menopause.

Please consult your doctor to find out what specific diseases or health conditions may put you at increased risk for osteoporosis.

A professionally installed and inspected PV system poses minimal increased risk for fire. All materials and equipment used in the installation are UCC and NEC (building codes) approved. Annual inspection and services will keep risks low. If there are circumstances that damage or affect your roof or panels, your should contact your PV installer for an inspection (to be safe).

Women remain the fastest growing group to be infected with HIV. In fact, today one out of every three people found to have HIV infection in the U.S. is a woman. Yet there are many gaps in our medical knowledge about women and HIV disease. There seem to be complex gender differences in both symptoms and drug side effects, as well as gynecological complications. Women with AIDS made up an increasing part of the epidemic.

Out of the one million people who die from cardiovascular disease each year, approximately 500,000 are women*. The disease kills more women each year than all cancers combined. A primary risk factor is elevated total cholesterol levels. A borderline cholesterol level is between 200 and 239 mg/dl and a high cholesterol level is greater than 240 mg/dl. Approximately 50 million American women have cholesterol levels over 200 mg/dl.

A:The risk of birth abnormalities is no greater in embryo adoption than in a couple’s own genetic pregnancy.